Taking into consideration that neutralizing antibodies against CCR5 are used in therapy for the management at the early stage of the acquiring human immunodeficiency virus (HIV) infection [95], our findings could unveil cellular events that support the onset of unpredictable adverse central effects in patients receiving the anti-CCR5- treatments or that, if infected with the HIV1 virus, produce circulating natural anti-CCR5 antibodies. Here, CCR5 is linked to HIV infectious disease.